Market closed
Taysha Gene Therapies/$TSHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Ticker
$TSHA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
73
Website
TSHA Metrics
BasicAdvanced
$353M
-
-$0.36
0.90
-
Price and volume
Market cap
$353M
Beta
0.9
52-week high
$4.32
52-week low
$1.19
Average daily volume
2M
Financial strength
Current ratio
5.419
Quick ratio
5.301
Long term debt to equity
86.238
Total debt to equity
88.863
Interest coverage (TTM)
-849.23%
Management effectiveness
Return on assets (TTM)
-32.51%
Return on equity (TTM)
-121.94%
Valuation
Price to revenue (TTM)
51.63
Price to book
4.93
Price to tangible book (TTM)
4.93
Price to free cash flow (TTM)
-5.273
Growth
Revenue change (TTM)
-46.07%
Earnings per share change (TTM)
-62.84%
3-year earnings per share growth (CAGR)
-57.45%
What the Analysts think about TSHA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
TSHA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TSHA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TSHA News
AllArticlesVideos
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·5 days ago
Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Taysha Gene Therapies stock?
Taysha Gene Therapies (TSHA) has a market cap of $353M as of March 12, 2025.
What is the P/E ratio for Taysha Gene Therapies stock?
The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of March 12, 2025.
Does Taysha Gene Therapies stock pay dividends?
No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Taysha Gene Therapies dividend payment date?
Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.